Qlaris Bio, Inc.
Our lead asset, QLS-111, has a unique mechanism of action designed to lower intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the trabecular meshwork, thereby reducing distal outflow resistance and lowering EVP. By reducing EVP and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow. QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.www.qlaris.bio
0
MENTIONS
0
EPISODES
0
PODCASTS
Search complete. 0 mentions across 0 episodes found for "Qlaris Bio, Inc.".
No mentions of “Qlaris Bio, Inc.”
Nothing in this time range.
Or search every podcast